To assess the activity and safety of sequential 177 Lu-PSMA-617 and docetaxel versus docetaxel on a background of androgen deprivation therapy (ADT) in men with de novo metastatic hormone-naïve prostate cancer (mHNPC).
To assess the activity and safety of sequential 177 Lu-PSMA-617 and docetaxel versus docetaxel on a background of androgen deprivation therapy (ADT) in men with de novo metastatic hormone-naïve prostate cancer (mHNPC).